Navigation Links
Martek and Ragasa Sign Multi-Year Exclusive Supply Agreement
Date:3/26/2009

Mexican Product Launch Planned for 2009

COLUMBIA, Md. and MONTERREY, Mexico, March 26 /PRNewswire-FirstCall/ -- DHA omega-3 innovator and maker of the life'sDHA(TM) brand, Martek Biosciences Corporation (Nasdaq: MATK) and Ragasa, one of Mexico's largest providers of raw and refined oil products and maker of Mexico's leading consumer cooking oil brand, Nutrioli, announced today that they have entered into a long-term supply agreement.

Under the terms of the agreement, Ragasa has agreed to purchase all of its DHA omega-3 needs from Martek and plans to launch a consumer product featuring Martek's flagship product, life'sDHA, in 2009. Ragasa will display the life'sDHA logo on the product packaging, and will also include the life'sDHA logo in related marketing, advertising and promotional materials.

"Martek finds it rewarding to partner with Ragasa, a Mexican agribusiness leader, to make life'sDHA more readily available to Mexican consumers of all ages," said David Abramson, Martek president.

"Martek's life'sDHA is a trusted, vegetarian and sustainable source of DHA, an important nutrient for brain, eye and heart health throughout life," said Alejandro Garcia, Ragasa partner general manager. "Ragasa is pleased to be working with Martek to bring this health-enhancing innovation to Mexican consumers."

DHA omega-3 is a long-chain omega-3 fatty acid that serves as a primary building block for the brain and the eyes and supports brain, eye and cardiovascular health throughout life. There is a large and growing body of scientific evidence demonstrating that people of all ages benefit from an adequate supply of DHA omega-3 in their diets. Scientific reviews highlight the importance of DHA omega-3 in proper brain and eye development and function, as well as its importance in cardiovascular health. Clinical studies are underway to evaluate the role of DHA in decreasing the prevalence of certain neurological disorders. Leading experts around the world have noted that DHA is an important nutrient for health throughout the life cycle. Yet despite its importance, most consumers do not get enough DHA in their diets.

Fish are often incorrectly thought to be the only source of DHA omega-3. However, life'sDHA offers a trusted, vegetarian form of DHA that contains no oceanic pollutants or toxins. Fish are sources of DHA because of the DHA-rich microalgae in their food chain; life'sDHA is derived directly from microalgae, a renewable, sustainable source of DHA that does not deplete ocean resources, and is produced entirely in the U.S. in an FDA-inspected facility. Today, life'sDHA is found in numerous foods, beverages and supplements for people of all ages. It is also the only source of DHA used in U.S. infant formula and is included in more than 99 percent of all formulas on the U.S. market, as well as in more than 200 brands of infant formula, nutritional supplements and functional foods sold in over 75 countries worldwide.

Ragasa is a leading Mexican agribusiness supplier for the food industry. Founded in 1917, Ragasa provides raw and refined oils for the food industry, as well as a number of finished oil products for consumers, including Nutrioli soybean oil, Oli vegetable oil, and Ave vegetable oil. Nutrioli is Mexico's leading consumer cooking oil brand sold in supermarkets.

Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the innovation and development of DHA omega-3 products that promote health and wellness through every stage of life. The company produces life'sDHA, a sustainable and vegetarian source of DHA omega-3, for use in foods, beverages, infant formula, and supplements, and life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, for use in infant formula. For more information on Martek Biosciences, visit http://www.martek.com/. For a complete list of life'sDHA products, visit http://www.lifesdha.com/.

Sections of this release contain forward-looking statements. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-K for the fiscal year ended October 31, 2008 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.

    Contact: Kyle Stults
             Investor Relations
             (410) 740-0081
             Investors@martek.com

             Cassie France-Kelly
             Public Relations
             (443) 542-2116
             cfrancekelly@martek.com


'/>"/>
SOURCE Martek Biosciences Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Martek to Announce First Quarter 2009 Results
2. Marteks lifesDHA(TM) Featured in Four New Products from Spectrum Organics
3. Marteks lifesDHA(TM) Now Available in Rachels(TM) Yogurt at Grocery Retailers Nationwide
4. Martek to Present at Upcoming Needham Conference
5. Australias Leading Juice Company Launches Juice Blend with Marteks lifesDHA(TM)
6. Sunkist Naturals Glorious Greens Smoothie Features Marteks lifesDHA
7. Martek Announces First Quarter 2008 Financial Results
8. Marteks lifesDHA(TM) Featured in Three New Offerings of Baby Food from Plum Organics
9. Summary Notice of Proposed Settlement and Settlement Hearing in Re Martek Biosciences Corp., Securities Litigation
10. Pocket Rocket Juice from Australias Boost Juice Features 700 mg of Marteks lifesDHA(TM)
11. Martek Announces Settlement of Class Action Lawsuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Datos Health , ... partnership with Med-e-Mass , the largest Electronic Medical Records (EMR) provider in South ... care plan incentives to a patient’s remote health progress, empowering the patient to take ...
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may be ... conditions and has helped many women become pregnant upon treating their diagnosis. ... and simple outpatient evaluations. We can provide the necessary information to diagnose ...
(Date:4/26/2017)... ... April 26, 2017 , ... Want to learn more about ... ) that demonstrates how this advanced plant breeding technology is a more efficient ... fewer resources. It highlights the business’ principles, research and collaboration efforts in this ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... is proud to announce that it has received 510(k) clearance from the U.S. ... Home and the MyoCycle Pro. , Both devices are stationary cycling systems that ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... have signed an agreement to be the preferred physical therapy provider for Derby ... returning them to Derby City CrossFit as quickly and effectively as possible, ProRehab’s ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research and ... Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 Mn ... by 2024, expanding at a CAGR of 5.6% from 2016 ...
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
Breaking Medicine Technology: